BLEMONT

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 217487
                    [Title] => Continue to warn patients about kava’s liver toxicity
                    [Summary] => The supplement kava, pulled from European markets and the subject of a Food and Drug Administration MedWatch alert after reports of liver injury, should not be used until more information is available about potential hepatotoxicity, as reported at a seminar on treating mood and anxiety disorders. If the patient insists on using kava, document your discussion about the warnings and monitor liver function tests said by a director of psychopharmacology, McLean Hospital, Blemont, Mass., and Harvard Medical School, Boston.
                    [DatePublished] => 2003-08-17 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Continue to warn patients about kava’s liver toxicity

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | August 17, 2003 - 12:00am

The supplement kava, pulled from European markets and the subject of a Food and Drug Administration MedWatch alert after reports of liver injury, should not be used until more information is available about potential...

Opinion